{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'If a IMP-related AE occurs in a patient that the Investigator judges as presenting a potential risk', 'to the patient for further dosing, the fitusiran dose may be held at the discretion of the', 'Investigator and the study Medical Monitor should be contacted.', '6.2.3.1.', 'LFT Criteria for Withholding, Monitoring and Stopping Fitusiran Dosing', '1. LFT results are to be obtained within 7 days prior to dosing and results are to be reviewed', 'prior to each dose of fitusiran. Central laboratory results are preferable. If not available,', 'local laboratory results may be used; however, if a local assessment is drawn, a serum', 'chemistry sample must also be drawn for analysis at the central laboratory.', '2. For any ALT or AST elevation >3x ULN, central laboratory results should be used to', 'guide subsequent monitoring as detailed in Table 3.', '3. For any ALT or AST elevation >3x ULN:', 'a.', 'Confirm using central laboratory, as soon as possible, ideally within 2 to 3 days, but', 'no later than 7 days.', 'b. Perform assessments per Table 3 and Table 6.', 'c. If an alternative cause is found, provide appropriate care.', '4. For any ALT or AST elevation >3x ULN without alternative cause that is accompanied', 'by clinical symptoms consistent with liver injury (eg nausea, right upper quadrant', 'abdominal pain, jaundice) or elevated bilirubin to >2x ULN or INR >1.5, permanently', 'discontinue dosing.', '5. For confirmed ALT or AST elevations >3x ULN without alternative cause and not', 'accompanied by symptoms or elevated bilirubin >2x ULN or INR >1.5, see Table 3', 'below:', 'Property of the Sanofi Group - strictly confidential', '43']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'Table 3:', 'Monitoring and Dosing Rules for Asymptomatic Patients with Confirmed', 'Isolated Elevations of ALT and/or AST >3x ULN, with No Alternative Cause', 'Identified', 'Transaminase Level', 'Action', '>3xto 5x ULN', 'May continue dosing', 'Evaluate the initial elevation in LFT per the following', 'assessments:', 'Table 6 (all assessments to be performed once)', 'Hematology, serum chemistry, LFT, and coagulation per', 'Table 5', 'AT', 'Monitor at least every two weeks (hematology, serum chemistry,', 'LFT, and coagulation per Table 5 and AT)', 'If elevation persists for >2 months, must discuss with the study', 'Medical Monitor before continuing dosing', '>5x to 8x ULN', 'Hold fitusiran dose until recovery to <1.5x ULN; may resume', 'dosing after discussion with the Medical Monitor', 'Evaluate the initial elevation in LFT per the following', 'assessments:', 'Table 6 (all assessments to be performed once)', 'Hematology, serum chemistry, LFT, and coagulation per', 'Table 5', 'AT', 'Monitor at least weekly (hematology, serum chemistry, LFT, and', 'coagulation per Table 5 and AT) until ALT and/or AST is declining on', 'two consecutive draws, then may decrease monitoring to biweekly', 'If ALT or AST rises to >5x ULN following repeat dosing,', 'permanently discontinue dosing', '>8x ULN', 'Permanently discontinue dosing after confirmation of the transaminase', 'value', 'Note: In addition to these criteria, other assessments or evaluations may be performed per', 'Investigator discretion, as appropriate.', '6.2.4.', 'Preparation, Handling, and Storage', 'Qualified staff at each clinical study center will be responsible for preparation of fitusiran doses,', 'according to procedures detailed in the Pharmacy Manual. No special procedures for the safe', 'handling of IMP are required.', 'Property of the Sanofi Group - strictly confidential', '44']\n\n###\n\n", "completion": "END"}